Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Analysts
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Renumeration

Press releases

All press releases Regulatory

Regulatory press release 2021-08-06

Xspray Pharma publishes interim report Q2 , January – June 2021

Regulatory press release 2021-07-28

Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2)

Regulatory press release 2021-05-20

Bulletin from the annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2021-05-06

Xspray Pharma publishes Interim Report Q1, January – March 2021

Regulatory press release 2021-04-20

Notice of annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2021-04-08

Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)

Regulatory press release 2021-03-19

Xspray Pharma publishes its annual report for 2020

Regulatory press release 2021-02-25

Xspray Pharma publishes Interim report Q4, January – December 2020

Regulatory press release 2021-02-17

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-01-29

Number of shares and votes in Xspray Pharma

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.

IR contact

Kerstin Hasselgren, Chief Financial Officer

+46 (0)70 311 16 83

info@xspray.com

Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com